The Anthos Therapeutics acquisition represents a homecoming for its drug abelacimab, which originated in Novartis’s labs.

Abelacimab showed a 60-70% reduction in bleeding events compared to rivaroxaban, leading to early trial termination. The trial's results suggest abelacimab could shift the standard of care by ...

Anthos was founded by private equity firm Blackstone's Life Sciences business and by Novartis in 2019 to develop, manufacture, and commercialise abelacimab, a treatment to prevent strokes and the ...

Favorable bleeding outcomes related to abelacimab have positioned the medication as a potential game changer in the treatment of atrial fibrillation. One of the core results from AZALEA-TIMI 71 ...

Reflects the promise of the novel Factor XI inhibitor class of medicines to help prevent strokes and other conditions as well as Abelacimab’s potential to provide superior safety CAMBRIDGE, ...

The deal is expected to close in H1 2025. Anthos’ abelacimab showed reduced bleeding risks in Phase 2 trials and is in three Phase 3 studies for clot prevention. Every week, our Whisper Index ...

Basel, February 11, 2025 – Novartis today announced that it has entered into an agreement to acquire Anthos Therapeutics, Inc., a Boston-based, privately held, clinical-stage biopharmaceutical ...

After securing the $14 billion acquisition of Boston's Karuna Therapeutics Inc. last year, Bill Meury has now locked in another big biotech deal. In his next chief executive gig after securing the ...

The acquisition represents a homecoming for Anthos’s main asset, abelacimab, a drug that originated in Novartis’s labs. Anthos launched in 2019 with $250 million from Blackstone Life Sciences ...

Reflects the promise of the novel Factor XI inhibitor class of medicines to help prevent strokes and other conditions as well as Abelacimab’s potential to provide superior safety “Abelacimab ...

Anthos was founded by private equity firm Blackstone's Life Sciences business and by Novartis in 2019 to develop, manufacture, and commercialise abelacimab, a treatment to prevent strokes and the ...

Anthos was founded by Blackstone Life Sciences and Novartis in 2019 with the exclusive global rights from Novartis to develop, manufacture, and commercialize abelacimab, a novel factor XI ...